Skip to content

    Recently Viewed

      Listening...

      lede-3 Ways Johnson & Johnson Is Innovating to Help Fight Tuberculosis.jpg

      3 ways Johnson & Johnson is innovating to help fight tuberculosis

      It’s one of the world’s deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. We’re taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.

      Share Article
      share to

      1.4 million. That’s how many people tuberculosis (TB) killed in 2019, despite it being a preventable and treatable disease.

      For years, one of the biggest impediments to global efforts to tackle TB has been growing resistance to the most commonly used medicines to treat the disease—in 2019 alone, there were nearly 400,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most commonly-used TB medications currently available.

      There’s also the hurdle of diagnosis: While detection numbers had been on the rise prior to the COVID-19 pandemic, there are still approximately 3 million people living with TB who don’t know they have the disease. And every individual who remains untreated can infect up to 15 additional people over the course of a year, further fueling the TB pandemic.

      COVID-19 is also posing new challenges. Not only do people with TB fear that they may be uniquely vulnerable to severe complications from COVID-19 if infected, but the pandemic has also disrupted already stretched systems of delivering TB care.

      “COVID-19 is threatening hard-won gains in the fight against TB,” says Ana-Maria Ionescu, TB Access Strategy & Impact Leader, Global Public Health, Johnson & Johnson. “At Johnson & Johnson, we are committed to doing our part, in collaboration with governments and partners, to ensure that patients continue to receive the care they need during these unprecedented times.”

      For example, in response to COVID-19, Johnson & Johnson launched the DR-TB Lifeline QuickFire Challenge, which is providing support to five organizations working to ensure continuity of care for drug-resistant TB (DR-TB) patients in India, the Philippines, South Africa and Ukraine.

      Before the pandemic, Johnson & Johnson also launched a historic 10-year initiative in 2018 aimed at helping improve disease detection; broaden access to its novel medicine for MDR-TB; and accelerate research to develop more next-generation medicines.

      It’s a critical project—and the company is well on its way to delivering on some of the key commitments.

      We’re highlighting some of the strides Johnson & Johnson made through the initiative to help bring us closer to a TB-free world.


      3-ways-tuberculosis-infographic-dec-9-02.jpg

      Johnson & Johnson’s Quest to End TB

      Read about how the company is working to improve detection, broaden access to treatment, and accelerate research and development for the disease over the next decade.

      More from Johnson & Johnson

      Innovation
      Blue latex-gloved hands holding a beaker filled with yellow liquid
      Innovation

      IBD rates are rising in communities of color. Can these innovators help?

      Scientists aren’t sure what’s behind the upward trend. That’s why Johnson & Johnson Innovation put out the call to address this troubling health disparity.
      Innovation
      DNA illustration genetic material
      Innovation

      Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way

      The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
      Health & wellness
      1123 BTN-Lung Cancer-Iede2.jpg
      Health & wellness

      By the numbers: Who gets lung cancer?

      Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.
      You are now leaving JNJ.com and going to a site with a different privacy policy. Please click below to continue to that site.